Our Client Corner: Perspectives from Founders, Financiers, and Friends podcast series hosted by Mintz Member Joshua Fox explores the dynamics of starting and running a business,.
Conflict Allegations Sufficient to Merit Inspection of Books and Records natlawreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from natlawreview.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SHANGHAI, Dec. 14, 2020 /PRNewswire/ 3SBio Inc. ( 3SBio ) s subsidiary, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd. ( Sunshine Guojian ) and Verseau Therapeutics, Inc. ( Verseau ) today announced the selection of a monoclonal antibody targeting VSIG4, as a licensed program under their partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a broad range of cancers. This is the second licensed program under the partnership agreement signed between the parties in 2019. The first licensed program was granted by Verseau to Sunshine Guojian for VTX-0811, a novel PSGL-1-targeted antibody in the field of immuno-oncology, on November 18, 2019.